Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy (IgAN), a disease with high unmet medical needs and no approved therapies. In addition, the Company is evaluating additional immunologic diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN).
Data Provided by Refinitiv. Minimum 15 minutes delayed.